Surgery for advanced rectal or anal cancer
Part of Cancer, Digestive system clinical trials.
This trial studies the results of a major surgery called pelvic exenteration for patients with advanced rectal or anal cancer that has spread to nearby tissues or bones but not to distant organs. The goal is to see how well the surgery works and how patients recover afterward.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 20 years or older.
- You must have rectal or anal cancer confirmed by a biopsy.
- Your cancer has spread to nearby areas like the sacrum (lower spine), prostate, or blood vessels, but it can still be fully removed with surgery.
- A team of doctors from different specialties has reviewed your case and agreed that surgery is a good option.
- Imaging scans (like MRI or PET/CT) show the cancer is removable and has not spread to distant parts of the body.
- You agree to be monitored after surgery and complete questionnaires about your recovery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether removing the rectal tumor locally (through the anus) can work as well as a more extensive operation after scans show no remaining cancer. It may help some people avoid bigger surgery if the cancer truly appears gone after treatment.
This trial looks at a specific type of rectal surgery after you’ve already finished chemo-radiation, aiming to remove the tumor while trying to preserve the anal sphincter (muscle control). It’s meant for people whose cancer can be safely operated on and who don’t have spread to distant organs.
This trial tests a combination of drugs given before surgery to shrink rectal cancer tumors and improve the chances of successful surgery. The drugs include an immunotherapy called serplulimab, chemotherapy (XELOX), and a targeted therapy called bevacizumab. This approach may help reduce the risk of the cancer coming back.
This trial compares standard chemotherapy to more extensive surgery (total mesorectal excision) for patients whose initial local surgery showed high-risk features like poor differentiation, lymphovascular invasion, or larger tumor size. It aims to find the best treatment to prevent cancer from coming back.
This trial compares two surgical approaches to remove rectal cancer tissue while aiming to preserve cure chances. It may help you see which approach fits your tumor location and health situation best.
This study looks at giving radiation and/or chemotherapy before surgery for rectal cancer that has come back in the pelvis. The goal is to see if this approach can shrink the tumor and make it easier to remove, potentially improving outcomes.
Hear when a new Rectal Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.